Flexible Dosing in in Atopic Dermatitis Treatment: Notes on Real-World Use with Raj Chovatiya, MD, PhD, MSCI

"After patients achieve meaningful improvement in terms of itch and skin signs by usually around the third or fourth month of therapy in our clinical studies, there's an opportunity to study these patients in terms of how they might do if they stop therapy or go on much less frequent dosing."

At the Revolutionizing Atopic Dermatitis 2025 meeting, well known researcher Raj Chovatiya, MD, PhD, MSCI, co-chair of the 2-day event, spoke on the topic of flexible medication dosing in adults being treated for atopic dermatitis. The context for his presentation was how dosing of the expanding number of drug classes for the chronic disease may be being tailored in real-world use to match the needs of individual patients and their specific treatment needs.

"What we really want to learn about is how people are mixing, matching and combining many of these therapies in the real world to give their patients excellent control, but also flexibility in terms of their treatment, especially when it comes to thinking about what they may need for a flare, what they may need for maintenance, what they may be using at certain times during the year," Chovatiya told Patient Care during an interview at the meeting. He goes into more detail in the short video above, taped onsite in Nashville, TN, June 6-7.

Chovatiya is clinical assistant professor of medicine at Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology + Immunology Research in Chicago, IL.